H-δ-Ava-NH-Phenyl | 115012-24-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-δ-Ava-NH-Phenyl
• 英文别名: 5-amino-N-phenylpentanamide
• CAS: 115012-24-3
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: SFFKZAAXPPFZGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  H-δ-Ava-NH-Phenyl 在 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 Thioacetic acid S-[(4-phenylcarbamoyl-butylcarbamoyl)-methyl] ester
  参考文献：
  名称：

  Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design

  摘要：

  In order to find novel non-hydroxamate histone deacetylase (HDAC) inhibitors, we synthesized several suberoylanilide hydroxamic acid (SAHA)-based compounds designed on the basis of the catalytic mechanism of HDACs. Among these compounds, 5b was found to be as potent as SAHA. Kinetic enzyme assays and molecular modeling suggested that the mercaptoacetamide moiety of 5b interacts with the zinc in the active site of HDACs and removes a water molecule from the reactive site of the deacetylation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.074
• 作为产物：
  描述：

  己二酸 在 palladium on activated charcoal 二苯基膦叠氮化物 、 氢气 、 三乙胺 作用下， 以 甲醇 、 苯 为溶剂， 生成 H-δ-Ava-NH-Phenyl
  参考文献：
  名称：

  Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design

  摘要：

  In order to find novel non-hydroxamate histone deacetylase (HDAC) inhibitors, we synthesized several suberoylanilide hydroxamic acid (SAHA)-based compounds designed on the basis of the catalytic mechanism of HDACs. Among these compounds, 5b was found to be as potent as SAHA. Kinetic enzyme assays and molecular modeling suggested that the mercaptoacetamide moiety of 5b interacts with the zinc in the active site of HDACs and removes a water molecule from the reactive site of the deacetylation. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.074

文献信息

• Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors
  作者：Chen Chen、Xinying Yang、Hao Fang、Xuben Hou

  DOI：10.1016/j.ejmech.2019.111563

  日期：2019.11

  Matrix metalloproteinases (MMPs) play important roles in many diseases including cancer. With moderate metal-binding affinity, 8-hydroxyquinoline has gained much interest in current drug design and development. Specially, it has been reported that 8-hydroxyquinoline derivatives serve as MMP-2 inhibitors with micromolar IC50 values. In the current study, a series of 8-hydroxyquinoline derivatives were

  基质金属蛋白酶（MMP）在包括癌症在内的许多疾病中都起着重要作用。具有适度的金属结合亲和力，8-羟基喹啉在当前的药物设计和开发中引起了很多兴趣。特别地，已经报道8-羟基喹啉衍生物用作具有微摩尔IC 50值的MMP-2抑制剂。在当前的研究中，设计并合成了一系列8-羟基喹啉衍生物，作为新的MMP-2和MMP-9抑制剂。活性最强的化合物5e和5h不仅对亚微摩尔水平的IC 50表现出对MMP-2 / 9的良好抑制活性，而且在A549细胞系中具有强大的抗增殖，抗侵袭和抗血管生成活性。免疫印迹也显示5e和5h下调A549细胞系中MMP-2和MMP-9的表达。此外，流式细胞术分析表明化合物5e可以促进A549细胞的体外凋亡。分子对接分析还揭示了MMP-2和MMP-9活性位点中5e的有利结合模式。
• Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
  申请人：Breslow Ronald

  公开号：US20070010536A1

  公开（公告）日：2007-01-11

  The present invention provides the compound having the formula: wherein each of R 1 and R 2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH 2 —; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.

  本发明提供了具有以下式子的化合物：其中R1和R2分别为取代或未取代的芳基、环烷基、环烷基氨基、萘基、吡啶氨基、哌啶基、叔丁基、芳氧基、芳基烷氧基或吡啶基；其中A为酰胺基、-O-、-S-、-NH-或-CH2-；n为3到8的整数。本发明还提供了一种选择性诱导肿瘤细胞生长停滞、终末分化和/或凋亡的方法，从而抑制这些细胞的增殖。此外，本发明还提供了一种治疗具有肿瘤细胞增殖特征的患者的方法。最后，本发明提供了一种包括药学上可接受的载体和上述化合物的治疗上可接受的剂量的药物组合物。
• Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones
  作者：Banerjee Riddhidev、Karaj Endri、Lamichhane Sabitri、N. Kotsull, Lauren、Kuganesan Nishanth、Isailovic Dragan、Pflum Mary Kay H、Slama James、Taylor William、Tillekeratne L. M. Viranga

  DOI：10.1016/j.ejmech.2022.114807

  日期：2022.12

  regulation of gene expression using histone deacetylase (HDAC) inhibitors is a promising strategy for developing new anticancer agents. The most common HDAC inhibitors are hydroxamates, which, though highly potent, have limitations due to their poor pharmacokinetic properties and lack of isoform selectivity. Trifluoromethylketones (TFMK) developed as alternatives to hydroxamates are rapidly metabolized to inactive

  使用组蛋白脱乙酰酶 (HDAC) 抑制剂对基因表达进行表观遗传调控是开发新型抗癌药物的一种有前景的策略。最常见的 HDAC 抑制剂是异羟肟酸盐，虽然其效力很高，但由于其药代动力学特性较差且缺乏同工型选择性而具有局限性。作为异羟肟酸替代品而开发的三氟甲基酮（TFMK）在体内迅速代谢为无活性的三氟甲醇，这阻碍了它们作为潜在候选药物的进一步发展。为了克服这一限制，我们设计了三氟丙酮酰胺（TFPA）作为 TFMK 替代品。酮羰基旁边额外的吸电子基团的存在使得酮的水合物形式更加稳定，从而防止其在体内代谢还原为醇。此外，这种结构修饰降低了 TFMK 基团作为共价弹头消除脱靶效应的潜力。抑制剂帽基团的额外结构变化使得类似物在细胞毒性测定中的IC 50值范围从高纳摩尔到低微摩尔，并且它们对癌细胞比正常细胞更具选择性。一些最活跃的类似物以低纳摩尔 IC 50值抑制 HDAC 酶，并且被发现对 HDAC8 比
• NPYY5 antagonists
  申请人：Shionogi&Co., Ltd.

  公开号：EP2014285A1

  公开（公告）日：2009-01-14

  The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof

  本发明提供了一种用作 NPY Y5 受体拮抗剂的药物组合物，该组合物由式（I）化合物组成： 其中 R1 是低级烷基、环烷基或类似物、 R2 是氢、低级烷基或类似物、 n 是 1 或 2、 X 是低级烯烃、低级烯烃、芳基、环烷烃或类似物、 Y 是 CONR7、CSNR7、NR7CO、NR7CS 或类似物、 Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物，R7 是氢或低级烷基、 其原药、药学上可接受的盐或溶液
• Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo
  作者：Yiyue Feng、Yingmei Lu、Junfang Li、Honghua Zhang、Zhao Li、Hanzhong Feng、Xuemei Deng、Dan Liu、Tao Shi、Weifan Jiang、Yongxing He、Jian Zhang、Zhen Wang

  DOI：10.1016/j.ejmech.2021.113888

  日期：2022.1